病理联系和多方位方法缓解铁和阿尔茨海默病的疾病
Hariharan Moorthy1, Shreyasri Sain1, Dikshaa Padhi1
1Bioorganic Chemistry Laboratory, New Chemistry Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Bengaluru, Karnataka 560064, India.
Journal of medicinal chemistry
|September 26, 2025
概括
铁亡是一种细胞死亡途径,涉及铁和脂质过氧化,有助于阿尔茨海默氏症 (AD) 神经退行. 针对GPX4和FSP1等铁灭细胞调节器,为AD提供了新的治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,其特征是神经退行.
- 目前针对粉样蛋白通路的AD治疗方法的有效性有限.
- 新出现的证据表明,依赖铁的脂质过氧化 (LPO) 驱动的细胞死亡 - - 铁亡 (ferroptosis) 有助于AD中的神经元损失.
研究的目的:
- 探索铁和阿尔茨海默病之间的病理相互作用.
- 确定向关键铁灭调节者的治疗潜力.
- 为开发用于AD的新型多功能治疗分子提供战略见解.
主要方法:
- 关于铁灭菌生物标志物和AD病理学的现有文献的综述.
- 分析铁二氧化稳定,脂质过氧化和抗氧化能力在阿尔茨海默病中的作用.
- 探索ferroptosis调节器GPX4和FSP1作为治疗点.
主要成果:
- 核心的铁灭生物标志物 (铁体平衡,LPO,降低抗氧化能力) 与AD的特征一致.
- 临床证据支持铁和AD之间的病理联系.
- 确定GPX4和FSP1是关键的铁灭调节体,在阿尔茨海默病中具有显著的治疗潜力.
结论:
- 铁亡是阿尔茨海默病中神经退行的一个重要因素.
- 向GPX4和FSP1等铁灭调节体,为阿尔茨海默病提供了一个有希望的治疗策略.
- 混合多功能分子的开发可以协同针对AD治疗的相互连接途径.
相关概念视频
01:22Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824
03:03Amyloid Fibrils
11.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.6K
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K